Antibody Targeted Amanitin Conjugates (ATAC): A New Payload Provides New Options for Cancer Therapy

Time: 2:00 pm
day: Day Two

Details:

  • Discussing a new payload with a new mode of action providing new options to fight cancer
  • The ATAC platform optimized the ADC technology for that payload
  • HDP-101 targeting BCMA is the first ATAC which cleared IND and is now in dose escalation in myeloma patients

Speakers: